Induction immune-checkpoint inhibitors for resectable oncogene-mutant NSCLC: A multicenter pooled analysis
Abstract Despite limited efficacy of immunotherapy for advanced non-small-cell lung cancer (NSCLC) with driver mutations, whether neoadjuvant immunotherapy could be clinically valuable in those patients warrants further investigation. We utilized 40 oncogene-mutant NSCLC treated with induction immun...
Kaydedildi:
| Asıl Yazarlar: | , , , , , , , , , , , , , , , , , |
|---|---|
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
Nature Portfolio
2022-09-01
|
| Seri Bilgileri: | npj Precision Oncology |
| Online Erişim: | https://doi.org/10.1038/s41698-022-00301-8 |
| Etiketler: |
Etiket eklenmemiş, İlk siz ekleyin!
|
